[HTML][HTML] Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label …
Y Okubo, H Takahashi, R Hino, K Endo… - Dermatology and …, 2022 - Springer
Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …
quality of life and increased disease burden due to itch or involvement of psoriasis in special …
[HTML][HTML] Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label …
Y Okubo, H Takahashi, R Hino, K Endo… - Dermatology and …, 2022 - ncbi.nlm.nih.gov
Methods PROMINENT, a phase 3b, open-label, single-arm study in Japan, enrolled adults≥
20 years of age with plaque psoriasis [static Physician Global Assessment (sPGA) 2 (mild) or …
20 years of age with plaque psoriasis [static Physician Global Assessment (sPGA) 2 (mild) or …
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single …
Y Okubo, H Takahashi, R Hino… - Dermatology and …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …
quality of life and increased disease burden due to itch or involvement of psoriasis in special …
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single …
Y Okubo, H Takahashi, R Hino, K Endo… - Dermatology and …, 2022 - europepmc.org
Methods PROMINENT, a phase 3b, open-label, single-arm study in Japan, enrolled adults≥
20 years of age with plaque psoriasis [static Physician Global Assessment (sPGA) 2 (mild) or …
20 years of age with plaque psoriasis [static Physician Global Assessment (sPGA) 2 (mild) or …
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single …
Y Okubo, H Takahashi, R Hino, K Endo… - Dermatology & …, 2022 - search.ebscohost.com
Introduction: Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …
quality of life and increased disease burden due to itch or involvement of psoriasis in special …